Jonathan Goldman
Cardiovascular Disease · Mill Valley, CANPI 1366550428
Payments from drug & device makers
Across 55 payments — averaging $7211.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$200K
- G1 Therapeutics, Inc.$60K
- Genmab A/s$54K
- Merck Healthcare Kgaa$49K
- Pfizer$19K
- Astrazeneca UK Limited$12K
- plus $2K from 1 others
Across 2 payments — averaging $1644.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
What the payments were for
- Food & beverage$72100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $200,166 |
| G1 Therapeutics, Inc. | 15 | $59,663 |
| Genmab A/s | 13 | $54,403 |
| Merck Healthcare Kgaa | 8 | $49,479 |
| Pfizer | 2 | $18,757 |
| Astrazeneca UK Limited | 6 | $11,707 |
| AstraZeneca | 3 | $2,483 |
How this compares
$396,657 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Mill Valley
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.